Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CDK12 G909E |
| Therapy | Enzalutamide |
| Indication/Tumor Type | prostate cancer |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CDK12 G909E | prostate cancer | predicted - resistant | Enzalutamide | Preclinical - Cell culture | Actionable | In a preclinical study, expression of CDK12 G909E in prostate cancer cells was associated with increased growth in the presence of Xtandi (enzalutamide) in culture (PMID: 36129942). | 36129942 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36129942) | CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. | Full reference... |